Latest News and Press Releases

Longeveron CEO Wa’el Hashad will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.

Toronto, Ontario, June 04, 2025 (GLOBE NEWSWIRE) -- LifeLabs, a leading provider of health diagnostics and laboratory services, is proud to announce the launch of a comprehensive portfolio of...

Maintains Brain Connectivity: GAL-201 prevents amyloid-beta (Aβ)–induced synaptic damage by maintaining long-term potentiation, a correlate for learning and memory.Improves Memory and Behavior:...

Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine.

Inflammasome-driven microglial inflammation key to accumulation of toxic phosphorylated alpha-synuclein leading to neurodegeneration and Parkinson's.

Longeveron selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition.

Longeveron announces Q1 2025 financial results & provides business update. Pivotal Phase 2 clinical trial achieves 95% enrollment. Expected full enroll Q2.

GAL-101 well tolerated; excellent safety and pharmacokinetic profile strongly supports oral administrationNext arms of study, including multiple ascending dose (MAD), underway and expected to complete...

Longeveron (LGVN) will report Q1 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close.

Neurogen Announces Partnership with NeuroX, a subsidiary of American TelePhysicians